Clinical trial NCT06757244: DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer
Official title: DOVIPA, a Phase II Study Evaluating Efficacy and Safety of DOstarlimab and Oral VItamin D3 With Folinic Acid, 5FU, Irinotecan Plus Oxalipaltin (mFOLFIRINOX) in Non Pretreated Metastatic PAncreatic Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Pancreas Neoplasms
Keywords: Pancreatic adenocarcinoma
metastatic PAncreatic Cancer
dostarlimab
vitamin D3
mFolfirinox
LV5FU
Lead sponsor: Hopital Foch
Sponsor class: OTHER
Collaborators: name: GlaxoSmithKline
First posted: 2025-01-03
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Methodology: prospective, multicentric, non-randomised, open-label, safety-run in, phase 2 study.
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to estimate the antitumor response of mFOLFIRINOX + Dostarlimab + oral HD vitamin D3 in patients with non-pretreated histologically confirmed metastatic Stage IV adenocarcinoma of the pancreas. The patients must have an Eastern Cooperative Oncology Group (ECOG)-Performance Status (PS) 0 or 1 and adequate organ functions.

The main objective of the study will be assessed by estimating Objective response rate (ORR) according to Response Evaluation Criteria version 1.1 (RECIST 1.1) in patients with pancreatic adenocarcinoma and measurable disease.

The Secondary objectives are :

* To assess the safety and tolerability of mFOLFIRINOX + Dostarlimab + HD Vitamin D according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 by evaluating the Median Progression Free Survival (mPFS) in months, the Median Overall Survival (mOS) in months, the Median Duration of Response (mDOR) in months and Clinical benefit rate according to RECIST 1.1 (CBR)
* To further evaluate the antitumor efficacy of mFOLFIRINOX + Dostarlimab + oral HD Vitamin D by evaluating the type, frequency, and severity of treatment-emergent adverse events (TEAEs); adverse events of special interest (AESIs); safety laboratory findings There are also exploratory objectives to better understand the pancreatic adenocarcinoma.

Participants will be cared for in the digestive oncology department. A selection review will be carried out to check compliance with the study eligibility criteria. Patients included in the study will be treated with 4 cycles of induction therapy. Each cycle lasts 6weeks and includes chemotherapy such as mFolfirinox D1,D15 and D29, combined with dostarlimab 500 mg every 3 weeks and daily oral vitamin D3.

At the end of the induction treatment period, maintenance treatment will be instituted with LV5FU chemotherapy combined with dostarlimab 1000 mg every 6 weeks and daily oral vitamine D3. Treatment will be maintained until progression or unacceptable toxicity.

Throughout this period, patients will be monitored for their safety. Imaging examinations will also be carried out to monitor the progression of tumour disease.


Eligibility criteria: Inclusion criteria

1. Histologically confirmed metastatic Stage IV adenocarcinoma of the pancreas
2. No prior treatment for stage IV pancreatic adenocarcinoma (prior adjuvant or neoadjuvant treatment is not allowed)
3. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1
4. Male and female patients 18 - 75 years
5. Measurable disease determined using guidelines of Response Evaluation Criteria In Solid Tumors (RECIST version 1.1)
6. Accessible tumor tissue available for fresh biopsy
7. Expected survival \>3 months
8. Men and women of child-bearing potential must agree to use adequate contraception.

   A female participant is eligible to participate if she is not pregnant or breastfeeding and at least one of the following conditions applies:
   * Is not a woman of childbearing potential (WOCBP), or
   * Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), from the screening visit to at least 6 months after the last dose of study treatment, and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of dostarlimab, and A WOCBP must have a negative highly sensitive pregnancy test (urine or serum, as required by local regulations) within 72 hours before the first dose of study treatment.

   Fertile men who are sexually active with a WOCBP must use a male condom plus spermicide during the trial and for 6 months after the last dose of study treatment administration. Male patients should also refrain from sperm donation throughout this period.
9. Laboratory values ≤1 week prior to randomization must be Adequate hematologic values

   * Platelet count ≥100,000 cells/mm3
   * Absolute neutrophil count \[ANC\] ≥1,500 cells/mm3
   * Hemoglobin ≥9 g/dL or ≥90 g/L) Adequate hepatic function
   * Aspartate aminotransferase \[AST/SGOT\] ≤2.5x Upper Normal Limit \[UNL\] (≤5x UNL if liver metastases present)
   * Alanine aminotransferase \[ALT/SGPT\] ≤ 2.5x Upper Normal Limit (≤5x UNL if liver metastases present)
   * Bilirubin ≤1.5x UNL
   * Serum albumin \> 3.0 g/dL Adequate renal function serum creatinine clearance CLcr ≥ 50 mL/min) (Cocroft-Gault Formula should be used for CrCl calculation) For participants not taking warfarin: INR \<1.5 or PT \<1.5 x ULN and either PTT or aPTT \<1.5 x ULN. Participants taking warfarin may be included on a stable dose with a therapeutic INR \<3.5 Uracilemia \< 16 ng/ml
10. Patients with history of hepatitis C (HCV) infection are eligible if HCV viral load is undetectable at screening. HCV screening tests are not required unless there is a known history of HCV infection.
11. No evidence of active infection and no serious infection within the past 30 days.
12. Patient able to understand and willing to sign and date the written voluntary informed consent form at screening visit prior to any protocol-specific procedures
13. Patient affiliated to a social security regimen

Non-inclusion criteria

1. Endocrine or acinar pancreatic carcinoma
2. Participant has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice.

   Note: Stable non-cirrhotic chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) is acceptable if participant otherwise meets entry criteria.
3. Major surgical procedure, significant traumatic injury within 28 days prior to study treatment start. Incompletely healed wounds or anticipation of the need for major surgical procedure during the course of the study
4. Known cerebral metastases, central nervous system (CNS), or epidural tumor
5. Prior anticancer treatment for adenocarcinoma of the pancreas including prior adjuvant or neoadjuvant treatment
6. Known dose tivity reaction to any of the components of study treatments.
7. Pregnancy (absence to be confirmed by β-hCG test) or breast-feeding period
8. Clinically relevant coronary artery disease or history of myocardial infarction in the last 6 months, or high risk of uncontrolled arrhythmia (for men: QTc ≥450 msec, for women: QTc ≥470 msec). Inclusion of patients with hypokalemia, hypomagnesemia and hypocalcemia (defined as results less than normal in Baseline testing) is not allowed.
9. Previous malignancy in the last 5 years except curative treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix
10. History or current evidence on physical examination of central nervous system disease or peripheral neuropathy ≥ grade 1 Common Toxicity Criteria for Adverse Events (CTCAE) v5.0.
11. Any significant disease which, in the investigator's opinion, would exclude the patient from the study.
12. Patient with a DPD deficiency or UGT1A1 homozygous 7/7; the test should be done for all patients before 5-FU administration, according to ANSM communication regarding recommendation about high risk of no testing DPD in patient before 5-FU administration
13. Has undergone prior allogeneic hematopoietic stem cell transplantation
14. Has had an allogeneic tissue/solid organ transplant
15. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent)
16. Participant has received systemic steroid therapy (\>10 mg daily prednisone or equivalent) within 7 days before the first dose of the study treatment or is receiving any other form of immunosuppressive medication. Replacement therapy (adrenal or pituitary insufficiency) is not considered a form of systemic therapy. Use of inhaled corticosteroids, local steroid injection, or steroid eye drops is allowed.
17. Participant has received a live vaccine within 30 days of planned start of study therapy. COVID-19 vaccines that do not contain live viruses are allowed. Note: mRNA and adenoviral-based COVID-19 vaccines are considered non-live.
18. History of or serology positive for HIV
19. Patients who have documented presence of HBsAg \[or HBcAb\] at Screening or within 3 months prior to first dose of study intervention are excluded. HBV screening tests are not required unless there is a known history of HBV infection.
20. Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
21. Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
22. Has an active infection requiring systemic therapy
23. Allergy: Participant cannot have history of severe allergic and/or anaphylactic reactions to chimeric, human or humanized antibodies or fusion proteins, sensitivity to any of the study treatments or components thereof, or a history of drug or other allergy that contraindicates their participation.

    In accordance with the updated SmPC of the products used in this trial, patient cannot be included in the following conditions:
    * patient has a peripheral sensitive neuropathy with functional impairment prior to first course (contra-indication use with Oxaliplatin)
    * concomitant use with St John's Wort - Chronic inflammatory bowel disease and/or bowel obstruction (contra-indication with Irinotecan)
    * patient which has been treated with brivudine, sorivudine or their chemically related analogues, which are potent inhibitors of the enzyme dihydropyrimidine dehydrogenase (DPD), which degrades fluorouracil. Fluorouracil must not be taken within 4 weeks of treatment with brivudine, sorivudine or their chemically related analogues (contra-indication with fluorouracil)
    * patient has diseases/conditions associated hypercalcaemia and / or hypercalciuria. - Calcium nephrolithiasis, nephrocalcinosis, D- hypervitaminosis
24. Being deprived of liberty or under guardianship
25. Potential participants who are pregnant, breastfeeding, or expecting to conceive children while receiving study treatment and/or unwilling to use highly effective contraception for up to 6 months after the last dose of study treatment are not eligible for the study.

Primary outcomes:
measure: Objective response rate (ORR) according to Response Evaluation Criteria version 1.1 (RECIST 1.1) in patients with pancreatic adenocarcinoma and measurable disease
timeFrame: 24 months
Secondary outcomes:
measure: Incidence of treatment-emergent adverse events (TEAEs) as assessed by CTCAE v5.0.
timeFrame: From the initiation of study treatment until 90 days after the last dose or 30 days following cessation of study intervention if the participant initiates new anticancer therapy, whichever is earlier, assessed up to 24 months"
measure: Incidence of participants with adverse events of special interest (AESIs) as assessed by CTCAE v5.0.
timeFrame: From the initiation of study treatment until 90 days after the last dose or 30 days following cessation of study intervention if the participant initiates new anticancer therapy, whichever is earlier, assessed up to 24 months"
measure: Number of Participants With Clinically Significant Changes in Hematology, Clinical Chemistry, Thyroid Function and Urinalysis Lab Parameters
timeFrame: From the initiation of study treatment until 90 days after the last dose or 30 days following cessation of study intervention if the participant initiates new anticancer therapy, whichever is earlier, assessed up to 24 months"
measure: Number of Participants With AEs Leading to Death
timeFrame: From the initiation of study treatment until 90 days after the last dose or 30 days following cessation of study intervention if the participant initiates new anticancer therapy, whichever is earlier, assessed up to 24 months"
measure: Median Progression Free Survival (mPFS) in months
timeFrame: 24 months
measure: Median Overall Survival (mOS) in months
timeFrame: 24 months
measure: Median Duration of Response (mDOR) in months
timeFrame: 24 months
measure: Number of Participants With Immune Related Adverse Events (irAEs)
timeFrame: From the initiation of study treatment until 90 days after the last dose or 30 days following cessation of study intervention if the participant initiates new anticancer therapy, whichever is earlier, assessed up to 24 months"
measure: Clinical benefit rate according to RECIST 1.1 (CBR)
timeFrame: 24 months
measure: Number of Participants With Adverse Events Leading to Discontinuation
timeFrame: From the initiation of study treatment until 90 days after the last dose or 30 days following cessation of study intervention if the participant initiates new anticancer therapy, whichever is earlier, assessed up to 24 months"
measure: Incidence of patient premature discontinuations (due to SAE or non-adherence to protocol)
timeFrame: From the initiation of study treatment until premature discontinuation due to serious adverse event or non adherence to protocol whichever is earlier, assessed up to 24 months"
measure: Incidence of dose modifications
timeFrame: From the initiation of study treatment until the last dose administration, assessed up to 24 months"
measure: Incidence of delays or interruptions in the administration of treatment due to the appearance of AEs
timeFrame: From the initiation of study treatment until the last dose administration, assessed up to 24 months"
Other outcomes:
Locations:
city: Marseille
country: France
facility: Marseille CRLCC
city: Nantes
country: France
facility: CHU Hôtel Dieu
city: Paris
country: France
facility: Hôpital Européen Georges Pompidou
city: Paris
country: France
facility: Hôpital Saint Antoine
city: Suresnes
country: France
facility: Hôpital Foch
Study officials:
affiliation: Hôpital Foch
name: Jaafar BENNOUNA, Pr
role: STUDY_DIRECTOR
References: